替诺福韦酯单药治疗慢性乙肝后肝硬化失代偿期的长期疗效随机对照研究

doi:10.3969/j.issn.1000-8535.2020.01.006

广州医药 ›› 2020, Vol. 51 ›› Issue (1): 24-27.DOI: 10.3969/j.issn.1000-8535.2020.01.006

替诺福韦酯单药治疗慢性乙肝后肝硬化失代偿期的长期疗效随机对照研究

唐帅

韶关市第一人民医院消化科 (韶关 512000)

收稿日期:2019-09-01 出版日期:2020-01-20 发布日期:2021-11-28
基金资助:
广东省韶关市卫生计生科研计划项目(Y19081)

Randomized controlled study of long-term efficacy of tenofovir disoproxil monotherapy in the treatment of decompensated cirrhosis after chronic hepatitis B

TANG Shuai

Department of Gastroenterology,the First People's Hospital of Shaoguan City,Shaoguan 512000, China

Received:2019-09-01 Online:2020-01-20 Published:2021-11-28

摘要/Abstract

摘要： 目的探讨替诺福韦酯单药治疗在慢性乙型肝炎(CHB)后肝硬化失代偿期(DCC)治疗中的长期应用价值。方法随机将84例CHB后DCC患者分为对照组及观察组,每组42例。对照组接受拉米夫定联合阿德福韦酯治疗,观察组接受替诺福韦酯治疗。对比两组12个月内治疗时间内的死亡率及肝癌发生率,并分析两组肝功能、肝硬化指标及Child-Pugh评分变化趋势,同时对比两组治疗过程中HBeAg转阴率、HBV-DNA转阴率及失代偿好转率。此外,对比两组治疗不良反应的发生率。结果在12个月的治疗时间内,两组死亡率及肝癌发生率比较,差异无统计学意义(P>0.05)。而两组治疗过程中ALT、AST、HA、LN、PCⅢ及Child-Pugh评分呈降低趋势,ALB呈升高趋势(P<0.05);治疗6个月及12个月时,治疗组ALT、AST、HA、LN、PCⅢ及Child-Pugh评分低于对照组,ALB高于对照组(P<0.05)。而两组12个月治疗完成后,HBeAg转阴率比较差异无统计学意义,但观察组HBV-DNA转阴率高于对照组(P<0.05)。此外,两组治疗不良反应发生率比较差异无统计学意义(P>0.05)。结论在CHB后DCC的治疗中,替诺福韦酯单药治疗方案具有良好的长期治疗效果。

关键词: 替诺福韦酯, 慢性乙型肝炎, 肝硬化失代偿期, 拉米夫定, 阿德福韦酯

Abstract: Objective To evaluate the long-term value of tenofovir disoproxil monotherapy in the decompensated cirrhosis(DCC) after chronic hepatitis B(CHB). Methods Eighty-four patients with DCC after CHB were randomly divided into control group and observation group, 42 cases in each group. The control group received lamivudine combined with adefovir dipivoxil, and the observation group received tenofovir disoproxil. Mortality and incidence of liver cancer within 12 months of treatment between the two groups were compared, and the change trend of liver function, liver fibrosis index and child-pugh score in the two groups were analyzed. At the same time,we compared the conversion rate of HBeAg, HBV-DNA and decompensated positive rate between the two groups. In addition, the incidence of adverse reactions were compared between the two groups. Results Within 12 months of treatment, there were no statistically significant differences in mortality and liver cancer incidence between the two groups(P>0.05). And during the treatment, the ALT, AST, HA, LN, PC Ⅲ and Child-Pugh score showed a decrease trend, ALB showed a increase trend(P<0.05). After 6-month and 12-month treatment, ALT, AST, HA, LN, PC Ⅲ Child-Pugh score of treatment group were lower than that of control group, ALB was higher than that of control group(P<0.05). After 12 months of treatment, the negative conversion rate of HBV-DNA in the observation group was higher than that of control group(P<0.05). In addition, there was no statistically difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Tenofovir disoproxil monotherapy has a good long-term therapeutic effect in the treatment of DCC after CHB.

Key words: Tenofovirdisoproxil, Chronic hepatitis B, Decompensated cirrhosis, Lamivudine, Adefovir dipivoxil

唐帅. 替诺福韦酯单药治疗慢性乙肝后肝硬化失代偿期的长期疗效随机对照研究[J]. 广州医药, 2020, 51(1): 24-27.

TANG Shuai. Randomized controlled study of long-term efficacy of tenofovir disoproxil monotherapy in the treatment of decompensated cirrhosis after chronic hepatitis B[J]. Guangzhou Medical Journal, 2020, 51(1): 24-27.

参考文献

[1] 杨玲玲,李君.乙型肝炎相关慢加急性肝衰竭诊断与预后评估的中国标准[J]. 中华临床感染病杂志,2019,12(1):22-23.
[2] 范丽,张婷.拉米夫定、阿德福韦酯、恩替卡韦治疗失代偿期乙型肝炎肝硬化临床研究[J]. 陕西医学杂志,2019,48(7):939-941.
[3] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J]. 实用肝脏病杂志,2016,19(3):389-400.
[4] 贾继东,魏来,侯金林,等. 《中国肝病诊疗管理规范》白皮书(节选)[J]. 临床肝胆病杂志,2014,30(3):197-209.
[5] 张爽,王锋,孟庆玲,等. 原发性肝癌患者流行病学与乙型肝炎病毒感染调查[J]. 中国疫苗和免疫,2018,24(2):133-136,151.
[6] 赵彩红,田志颖,张丽贤, 等.乙肝肝硬化患者中微小RNA-21、Th9的表达及其对肠道屏障功能调控机制的影响[J]. 实用医学杂志,2019,35(8):1204-1207.
[7] 张丽娜,蒋明光,黄启功, 等.水飞蓟素胶囊联合阿德福韦酯、拉米夫定治疗对失代偿期乙肝肝硬化患者肝功能及血清病毒学指标的影响[J]. 广西医科大学学报,2019,36(6):952-956.
[8] 冯静,张萍,邓菲, 等.乙肝抗病毒药物苦参碱联合拉米夫定对乙肝病毒DNA聚合酶活性的影响[J]. 中药药理与临床,2017,33(6):89-92.
[9] 王云.阿德福韦酯的药理作用与临床评价[J]. 中国药房,2010,21(34):3245-3246.
[10] 范凌,纪风兵,杨军, 等.拉米夫定联合阿德福韦酯对慢性乙型肝炎肝硬化患者预后、Th22细胞及IL-22表达的影响分析[J]. 中国医学前沿杂志(电子版),2018,10(10):98-101.
[11] 陈欣,陈立冬,李庭红.替诺福韦酯治疗多重耐药的乙型肝炎肝硬化患者疗效初步研究[J]. 实用肝脏病杂志,2018,21(5):681-684.

替诺福韦酯单药治疗慢性乙肝后肝硬化失代偿期的长期疗效随机对照研究

Randomized controlled study of long-term efficacy of tenofovir disoproxil monotherapy in the treatment of decompensated cirrhosis after chronic hepatitis B

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价